Patents by Inventor Paul J. Conlon
Paul J. Conlon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 6933274Abstract: The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.Type: GrantFiled: January 8, 2003Date of Patent: August 23, 2005Assignee: Neurocrine Biosciences, Inc.Inventors: Amitabh Gaur, Nicholas Ling, Paul J. Conlon
-
Publication number: 20040214775Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.Type: ApplicationFiled: April 8, 2004Publication date: October 28, 2004Applicants: Neurocrine Biosciences, Inc., Stanford University Medical CenterInventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
-
Patent number: 6740638Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.Type: GrantFiled: October 11, 2002Date of Patent: May 25, 2004Assignees: Neurocrine Biosciences, Inc., Stanford University Medical CenterInventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
-
Publication number: 20040082503Abstract: The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.Type: ApplicationFiled: January 8, 2003Publication date: April 29, 2004Applicant: Neurocrine Biosciences, Inc.Inventors: Amitabh Gaur, Nicholas Ling, Paul J. Conlon
-
Publication number: 20030114380Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.Type: ApplicationFiled: October 11, 2002Publication date: June 19, 2003Applicant: Neurocrine Biosciences, Inc.Inventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
-
Patent number: 6562942Abstract: The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues arc provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.Type: GrantFiled: June 7, 2001Date of Patent: May 13, 2003Assignee: Neurocrine Biosciences, Inc.Inventors: Amitabh Gaur, Nicholas Ling, Paul J. Conlon
-
Patent number: 6489299Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.Type: GrantFiled: November 19, 2001Date of Patent: December 3, 2002Assignees: Stanford University Medical Center, Neurocrine Biosciences, Inc.Inventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
-
Publication number: 20020086976Abstract: The present invention is directed toward peptide analogues of human myelin basic protein. The peptide analogue is at least seven amino acids long and derived from residues 86 to 99 of human myelin basic protein. The analogues are altered from the native sequence at least at positions 91, 95, or 97. Additional alterations may be made at other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating multiple sclerosis.Type: ApplicationFiled: December 11, 2001Publication date: July 4, 2002Applicant: Neurocrine Biosciences, Inc.Inventors: Nicholas Ling, Amitabh Gaur, Paul J. Conlon, Lawrence Steinman
-
Publication number: 20020058627Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.Type: ApplicationFiled: November 19, 2001Publication date: May 16, 2002Applicant: Neurocrine Biosciences, Inc.Inventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
-
Patent number: 6369033Abstract: Peptide analogues of human myelin basic protein containing residues 87-99 are provided. Residue 91 of the peptide analogues is altered from the L-lysine residue found in the native protein to any other amino acid. Pharmaceutical compositions of the peptide analogues are provided. In addition, the peptide analogues are administered to patients with multiple sclerosis.Type: GrantFiled: October 20, 1997Date of Patent: April 9, 2002Assignees: Stanford University Medical Center, Neurocrine Biosciences, Inc.Inventors: Lawrence Steinman, Nicholas Ling, Paul J. Conlon, Amitabh Gaur
-
Patent number: 6329499Abstract: The present invention is directed toward peptide analogues of human myelin basic protein. The peptide analogue is at least seven amino acids long and derived from residues 86 to 99 of human myelin basic protein. The analogues are altered from the native sequence at least at positions 91, 95, or 97. Additional alterations may be made at other positions. Pharmaceutical compositions containing these peptide analogues are provided. The peptide analogues are useful for treating multiple sclerosis.Type: GrantFiled: November 18, 1994Date of Patent: December 11, 2001Assignee: Neurocrine Biosciences, Inc.Inventors: Nicholas Ling, Amitabh Gaur, Paul J. Conlon, Lawrence Steinman
-
Patent number: 6197926Abstract: The present invention is directed toward peptide analogues of insulin B chain that are generally derived from peptides comprising residues 9 to 23 of the native B chain sequence. The analogues are altered from the native sequence at position 12, 13, 15 and/or 16, and may be additionally be altered at position 19 and/or other positions. Pharmaceutical compositions containing these peptide analogues arc provided. The peptide analogues are useful for treating and inhibiting the development of diabetes.Type: GrantFiled: February 23, 1999Date of Patent: March 6, 2001Assignee: Neurocrine BiosciencesInventors: Amitabh Gaur, Nicholas Ling, Paul J. Conlon
-
Patent number: 5948764Abstract: The present invention is directed toward peptide analogues of human myelin basic protein for use in the treatment of multiple sclerosis. Within one aspect, peptide analogues suitable for treating multiple sclerosis are provided which are at least seven amino acids long and derived from residues 86 to 99 of human myelin basic protein. In addition, such analogues may be altered from the native sequence at positions 87, 88, 97, 98 or 99 to a D-amino acid. Additional alterations may be made at other positions. Pharmaceutical compositions containing these peptide analogues are also provided, as well as methods for treating multiple sclerosis.Type: GrantFiled: January 9, 1997Date of Patent: September 7, 1999Assignee: Neurocrine Biosciences, Inc.Inventors: Amitabh Gaur, Paul J. Conlon, Nicholas Ling
-
Patent number: 5945401Abstract: Peptides and peptide analogues of the 65 kD isoform of human glutamic acid decarboxylase are provided for use in the treatment and prevention of diabetes. Peptide analogues contain generally from one to three amino acid alterations. Peptides and analogues may be used to diagnose diabetes and detect a predisposition to diabetes.Type: GrantFiled: June 23, 1995Date of Patent: August 31, 1999Inventors: Paul J. Conlon, Nicholas Ling, Amitabh Gaur, R. David G. Leslie, Marco Londei
-
Patent number: 5484887Abstract: Interleukin 1 has been purified by use of various techniques including ion exchange chromatography and dye-ligand affinity chromatography. By these techniques, interleukin 1 has been purified to homogeneity. The high purification of interleukin 1 has enabled the amino acid composition of this protein to be ascertained and its amino acid sequence to be partially determined.Type: GrantFiled: November 30, 1984Date of Patent: January 16, 1996Assignee: Immunex CorporationInventors: Shirley R. Kronheim, Carl J. March, Paul J. Conlon, III, Thomas P. Hopp
-
Patent number: 5122459Abstract: Double-stranded cDNA is prepared from polyadenylated RNA extracted from activated human peripheral blood adherent mononuclear cells. The cDNA is inserted within a plasmid vector and then the recombinant plasmid employed to transform an appropriate host. Transformed hosts are identified and grouped into pools. Plasmid DNA prepared from these pools is hybridized with a labeled, synthetic oligonucleotide probe corresponding to a portion of the amino acid sequence of the interleukin 1 protein. Pools of host cells that provide a positive signal to the probe are identified, plated out and then employed in direct bacterial colony hybridization with the same probe, thereby to isolate the particular positive colony. Plasmid DNA is prepared from this colony and characterized by restriction enzyme mapping and sequencing by chain-termination method. The coding region for the IL-1 gene is inserted into a shuttle vector for amplification of the vector followed by expression of functional IL-1.Type: GrantFiled: November 30, 1989Date of Patent: June 16, 1992Assignee: Immunex CorporationInventors: Paul J. Conlon, III, David j. Cosman, Kenneth H. Grabstein, Thomas P. Hopp, Shirley R. Kronheim, Alf D. Larsen, Carl J. March, Virginia L. Price, Douglas P. Cerretti
-
Patent number: 5078996Abstract: Macrophages and precursor monocytes are activated to exhibit tumoricidal activity by stimulation solely with granulocyte-macrophage colony stimulating factor. A patient suffering from tumors can be treated by direct administration of therapeutically effective quantities of activated granulocyte-macrophage colony stimulating factor. Homogeneous granulocyte-macrophage colony stimulating factor for use in activating macrophages and monocyte precursors is prepared by recombinant DNA techniques. The gene coding for granylocyte-macrophage colony stimulating factor is isolated and then recombinant protein product expressed in an appropriate expression system. The granulocyte-macrophage colony stimulating factor recovered from the expression system is purified to homogeneity by reverse phase high-performance liquid chromatography.Type: GrantFiled: July 31, 1986Date of Patent: January 7, 1992Assignee: Immunex CorporationInventors: Paul J. Conlon, III, Kenneth H. Grabstein
-
Patent number: 4782137Abstract: A hybrid polypeptide composed of an identification peptide and a desired functional protein are produced by recombinant DNA techniques. A DNA expression vector is constructed that includes segments of DNA coding for the identification peptide and the desired functional protein. The identification peptide consists of a highly antigenic N-terminal portion and a C-terminal linking portion that connects the identification peptide to the N-terminal of the functional protein. The linking portion of the identification peptide is cleavable at a specific amino acid residue adjacent the functional protein by use of a sequence specific proteolytic enzyme or chemical proteolytic agent. The hybrid polypeptide expressed by the host cells transformed by the cloning vector is removed therefrom and purfied by affinity chromatography techniques by use of an immobilized ligand specific to the antigenic portion of the identification peptide.Type: GrantFiled: July 23, 1987Date of Patent: November 1, 1988Assignee: Immunex CorporationInventors: Thomas P. Hopp, Susan L. Bektesh, Paul J. Conlon, III, Carl J. March
-
Patent number: 4703004Abstract: A hybrid polypeptide composed of an identification peptide and a desired functional protein are produced by recombinant DNA techniques. A DNA expression vector is constructed that includes segments of DNA coding for the identification peptide and the desired functional protein. The identification peptide consists of a highly antigenic N-terminal portion and a C-terminal linking portion that connects the identification peptide to the N-terminal of the functional protein. The linking portion of the identification peptide is cleavable at a specific amino acid residue adjacent the functional protein by use of a sequence specific proteolytic enzyme or chemical proteolytic agent. The hybrid polypeptide expressed by the host cells transformed by the cloning vector is removed therefrom and purified by affinity chromatography techniques by use of an immobilized ligand specific to the antigenic portion of the identification peptide.Type: GrantFiled: January 24, 1984Date of Patent: October 27, 1987Assignee: Immunex CorporationInventors: Thomas P. Hopp, Susan L. Bektesh, Paul J. Conlon, III, Carl J. March
-
Patent number: 4658018Abstract: Colony stimulating factor derived from malignant cells has been purified by use of various techniques including multiple high performance liquid chromotography steps. By this technique, colony stimulating factor has been resolved into distinct species, and one of the species denominated as CSF-2A, has been purified to homogeneity. The high purification of the CSF-2A has enabled the amino acid composition of this protein molecule to be partially sequenced with an automated sequencer.Type: GrantFiled: March 13, 1984Date of Patent: April 14, 1987Assignee: Immunex CorporationInventors: David L. Urdal, Carl J. March, Diane Y. Mochizuki, Paul J. Conlon, III